Padcev™ plus keytruda™ significantly improves survival for certain patients with bladder cancer when given before and after surgery
Pfizer Inc. and Astellas Pharma Inc. announced positive topline results from the Phase 3 EV-303 clinical trial (also known as KEYNOTE-905).